Clinical Trials for Mesothelioma Patients—A Study of Azacitidine in combination with Temo/Azac: Outcomes Measures

Read about the outcomes measures for a current clinical trial about the use of a Phase I dose study of Azacitidine in combination with Temo/Azac for patients with mesothelioma. Please note: this information is provided by Weitz & Luxenberg for informational purposes only.

Primary Outcome Measures:

The primary endpoint is dose limiting toxicity

Secondary Outcome Measures:

Clinical response, time to progression and overall survival.

Estimated Enrollment: 24

Study Start Date: October 2007

Estimated Study Completion Date: October 2009

Estimated Primary Completion Date: October 2009 (Final data collection date for primary outcome measure)

Intervention Details:

Drug: Azacitidine In Combination With Temozolomide mg, oral

Courtesy of ClinicalTrials.gov, a service of the U.S. National Institutes of Health

If you or a loved one has been diagnosed with an Asbestos illness like mesothelioma, lung cancer or asbestosis, complete the form on this page to get a FREE and prompt review of your case by a leading Asbestos attorney. Weitz & Luxenberg is a leading mesothelioma law firm with a substantial history of success in asbestos exposure cases.